Author: admin

PixNova AI Launches Revolutionary Video and Photo Face Swap Technology, Redefining Creative Media Standards

“PixNova AI”
New AI Face Swap Engine Delivers Unprecedented Speed, Accuracy, and Creative Freedom

PixNova AI, a global leader in AI-powered image and video generation, today announced the launch of its next-generation Video Face Swap and Photo Face Swap technology. This breakthrough upgrade significantly enhances face swap accuracy and realism while dramatically improving processing speed, empowering creators, film studios, short-form video influencers, and everyday users with a faster, more natural face-swapping experience.

About PixNova AI

PixNova AI is an all-in-one AI image and video creation platform dedicated to providing creators worldwide with efficient and intelligent visual production tools. The platform integrates cutting-edge AI capabilities, including artistic image generation, AI photo editing, AI image to video, video generation, high-resolution upscaling, background removal, and advanced face swap features. Without the need for complex post-production skills, users can generate high-quality images and videos in just a few simple steps or with short text prompts.

Since its launch, PixNova AI has supported millions of creators across industries including advertising, filmmaking, social media, e-commerce, and game art. With its user-friendly interface, powerful rendering capabilities, and unmatched creative flexibility, PixNova AI is quickly becoming the preferred visual generation and editing platform for creators worldwide.

Key Upgrade Highlights:

  • Real-Time Video Face Swap – Supports high-frame-rate processing, completing short video swaps in seconds.

  • High-Precision Photo Face Swap – Preserves skin texture, lighting, and color consistency for seamless, natural results.

  • Multi-Scene Compatibility – Works with movie clips, commercials, short videos, selfies, and group photos.

  • One-Click Batch Processing – Swap faces in multiple photos or videos at once, saving significant production time.

  • Privacy & Copyright Protection – All processing is done in encrypted cloud environments, with no data storage.


How to Use AI Face Swap for Video & Photo on PixNova AI:

  1. Visit the PixNova AI website and log in to your account.

  2. Upload the video or photo you want to edit.

  3. Upload or select your target face image.

  4. Click “Generate” — the AI will automatically match and render the swap.

  5. Download your finished result for social media, short-form platforms, or personal projects.


PixNova AI CEO Jack Xiong commented:

“We have achieved global leadership not only in algorithm precision and rendering speed but also in making face-swapping accessible to everyone. Whether you’re a filmmaker, content creator, or casual user, you can now produce results that rival professional post-production — all in just a few steps. This is the beginning of a new era for creative media.”

With this revolutionary upgrade, PixNova AI further solidifies its position as a leader in global AI-driven media processing, opening new creative possibilities for advertising, post-production, and social media storytelling.

Media Contact
Company Name: PixNova AI
Contact Person: Jack Xiong
Email: Send Email
Phone: 85257490148
Country: HongKong
Website: https://pixnova.ai/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PixNova AI Launches Revolutionary Video and Photo Face Swap Technology, Redefining Creative Media Standards

Coastal Comeback: Why the Great British Seaside Holiday Is Here to Stay

“Photograph: Peter Lourenco”
The British seaside holiday is evolving rather than disappearing. While overnight stays have declined, day trips and short breaks are growing in popularity. Resorts are adapting with modern attractions and events, ensuring the coast remains a beloved and resilient destination.

Once defined by deckchairs, sticks of rock, and donkey rides along the sand, the Great British seaside holiday has long been a national tradition. While its form has changed over the decades, its appeal in 2025 remains undeniable. The difference is in how people are choosing to enjoy it.

The post-war boom of the 1950s and 60s saw families flock to the coast for one or two weeks each summer. These extended stays cemented resorts like Blackpool, Brighton, Skegness, and Scarborough as household names. Over time, however, cheap package holidays abroad, low-cost flights, and the growing popularity of city breaks began to erode the dominance of the coastal getaway.

Today, the seaside is still a draw—but for many, it’s now a shorter escape. Tourism data shows that domestic overnight trips to the coast fell from 12.5 million in 2023 to 11.1 million in 2024, with overall spending down 4% year-on-year. At the same time, day visits are increasing, suggesting people still value the coast but are spending less time—and money—there.

Economic pressures are a significant factor. Rising costs for accommodation, food, and activities have made longer stays less affordable. The availability of budget flights to destinations with guaranteed sunshine has also shifted holiday habits. But the move towards shorter, more spontaneous trips is not solely about money; it reflects a broader cultural change towards flexible, bite-sized leisure.

Some resorts have adapted to this shift more successfully than others. In Lincolnshire, Skegness and Mablethorpe remain busy in summer, but much of the footfall comes from day-trippers. Hotels and guesthouses report fewer week-long bookings, while attractions such as arcades, mini-golf, and traditional funfairs continue to benefit from passing visitors.

Nationally, businesses that have diversified their offer are faring better. Butlin’s, the iconic holiday resort brand, continues to attract families for multi-day breaks while also catering to the growing demand for day passes. In East Yorkshire, destinations like Bridlington and Hornsea have maintained a balance between short-term guests and longer-term stays, aided by a mix of events, upgraded facilities, and improved transport links.

Despite these shifts, the emotional connection to the seaside remains strong. Generations of Britons associate the coast with childhood memories—building sandcastles, exploring rock pools, and enjoying fish and chips on the promenade. This nostalgia, paired with the sensory pleasures of sea air and open skies, ensures that even as the format changes, the draw endures.

Seasonality remains a challenge. Many coastal businesses see visitor numbers spike during warm summer weeks and drop sharply in winter. Rising operating costs have intensified the need for a year-round offer, prompting some resorts to introduce festivals, indoor attractions, and wellness retreats to spread tourism more evenly across the calendar.

Local councils and tourism boards are also playing a role in the seaside’s evolution. Investment in promenade upgrades, beach cleaning, and heritage restoration is helping to refresh the appeal of traditional resorts. Meanwhile, marketing campaigns are increasingly focused on positioning the seaside as a destination not only for families, but also for couples, groups of friends, and solo travellers.

The Great British seaside holiday of 2025 may not look exactly like the extended stays of the past, but its cultural significance is intact. Visitors may be more likely to arrive for a day or weekend rather than a fortnight, but the essence—sea, sand, and a sense of escape—remains unchanged.

With its blend of nostalgia and adaptability, the seaside is proving resilient. It has weathered competition from foreign travel, shifting economic conditions, and changing leisure patterns. Today’s holidaymakers are also looking for ways to make their trips more affordable, and sites like Vouchersgo—offering the latest verified discount codes for for everything from travel essentials and hotel stays to dining, clothing, and more—are helping them do just that. In the process, the seaside has found new ways to stay relevant, ensuring that future generations will still pack buckets, spades, and beach towels for a trip to the coast.

Media Contact
Company Name: VouchersGo
Email: Send Email
Phone: 13219752289
Address:Unit 402, 4f Fairmont House No.8 Cotton Tree Drive Admiralty
State: Hong Kong
Country: China
Website: https://www.vouchersgo.co.uk

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Coastal Comeback: Why the Great British Seaside Holiday Is Here to Stay

Singapore’s New Friend in the Block Redefines Venture Capital

“New Friend in the Block: An Evolution of Venture Capital for the AI Age”
Valven Studio is a Singapore‑based venture studio redefining VC. Instead of making many bets, it invests in a few high‑conviction startups and embeds its partners in the team. A rigorous three‑stage diligence and scorecard choose founders; then playbooks for product or distribution guide growth. Matthew Chew, Michel Padrón and Juan Roldán provide hands‑on product, growth and tech expertise to help founders go from 0.5 to 1.

Singapore – 13 August, 2025 – Valven Studio, a venture studio headquartered in Singapore, announces its arrival as a new alternative to venture capital. Born from the frustrations of the traditional VC model—where more than 75 % of VC‑backed startups never return capital and founders are often left without operational support (1) — Valven offers a founder‑friendly partnership that blends capital with hands‑on execution.

“We’re not here to spray and pray; we’re here to build,” said Matthew Chew, General Partner and Product Visionary. “Our approach embeds experienced operators directly into the startup team to turn data into decisive action and tackle overlooked problems.”

Beyond VC: How the Model Works

Valven’s model starts with a structured diligence process to evaluate potential partners. The three stages include:

  • Founder & Vision Interview – an assessment of character, resilience and coachability (2). Valven looks for founders who combine clear vision with intellectual humility and openness to strategic feedback.

  • Business & GTM Deep Dive – pressure‑testing the business model, unit economics and go‑to‑market strategy. The team assesses revenue streams, pricing, distribution engine and the founder’s ability to acquire customers.

  • Product & Tech Deep Dive – a comprehensive review of the product’s current state, architecture and scalability. Valven classifies the technical maturity as build, scale or rebuild, evaluating code quality, infrastructure and security.

Findings from the diligence process feed into the Valven Scorecard, which quantifies factors such as founder excellence, business model maturity, distribution readiness and technical foundation (3). Opportunities with strong scores move forward into one of two operational playbooks:

  1. Playbook A – Strong Product, Weak Distribution. For startups with validated products but limited customer acquisition, Valven’s Growth Partner leads the development of a scalable distribution engine, from founder‑led content strategies to paid growth campaigns. The Technical Partner ensures the product infrastructure can support rapid growth.

  2. Playbook B – Strong Distribution, Weak Product. For ventures with proven customer acquisition but technical gaps, Valven’s Technical Partner acts as interim head of engineering, defines the roadmap, builds the team and upgrades the product, while the Growth Partner optimizes revenue from existing channels.

Unlike typical VCs that make dozens of bets and hope a few hit, Valven invests in fewer ventures and commits deeply. Venture studios worldwide show that studio‑backed companies have about 30 % higher success rates than typical VC‑backed startups, with average IRRs of 53–60 % versus 21–22 % for traditional funds. Valven’s approach aims to replicate these outcomes in Southeast Asia.

Hands‑On Partners, Not Just Investors

Valven’s general partners bring complementary expertise honed through building and scaling ventures:

  • Matthew Chew – General Partner & Product Visionary. A serial founder and product strategist, Matthew believes entrepreneurship is about building tools that render old ways obsolete. He emphasizes rigorous analysis married with swift action and invites founders to harness technology to build a future that matters.

  • Michel Padrón – General Partner & Growth Strategist. Michel has built, scaled and exited ventures across fintech, AI and blockchain, learning from successes and failures. As a fractional founder, he merges engineering precision with business leadership to help startups avoid common growth pitfalls. He helps founders build distribution engines and optimize customer acquisition.

  • Juan Roldán – General Partner & Technical Strategist. Fascinated by how things work since childhood, Juan approaches the CTO role as a business enabler. He ensures technology decisions support the company’s vision, builds products that are both technically sound and commercially successful and thrives on bridging the gap between code and customer.


From 0 to 0.5 Is Easy – Valven Takes You from 0.5 to 1

Many accelerators and incubators help founders build a minimum viable product. Valven focuses on the messy 0.5–to–1 phase—where companies have an MVP and initial customers and need to scale quickly (4). By embedding its partners directly into the team, Valven provides technical leadership, go‑to‑market strategy and funding architecture, giving founders a co‑builder rather than just a cheque. The firm’s resource deployment model emphasises deep integration and shared accountability: Valven team members work alongside founder teams, sharing both the risk and the upside.

Structured Yet Flexible Engagement

After a playbook is selected, Valven helps founders secure the capital necessary for execution. Playbook A typically requires US$50K–US$250K for marketing, growth hiring and infrastructure; Playbook B needs US$100K–US$400K to hire engineers and build a robust product (5). Funding may come from existing company capital, a bridge investment from Valven’s partners or an orchestrated angel round. Before fully engaging, a five‑stage engagement sequence ensures both sides are ready—covering diligence and vote, funding plan, letter of intent, capital confirmation and definitive agreements. This sequencing protects resources, validates readiness and aligns expectations.

A Catalyst for Singapore’s Startup Ecosystem

Singapore has long been a hub for venture capital and innovation, yet many founders remain underserved by traditional investors. Valven Studio aims to bridge the gap between early traction and scalable success, bringing an AI‑enabled venture studio model that prioritizes diversity, founder empowerment and operational excellence. By investing in fewer, higher‑conviction bets and providing hands‑on operators, Valven offers investors a more thorough due‑diligence process and founders a partner who will build alongside them. The team invites ambitious founders and forward‑thinking investors to learn more and explore detailed insights in Valven’s Diligence Process, Partnership Evaluation and Playbook Execution series.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Valven Studio
Contact Person: Michel Padrón
Email: Send Email
Country: Singapore
Website: https://valvenstudio.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Singapore’s New Friend in the Block Redefines Venture Capital

Neurofibromatosis Type 1 Market Expected to Gain Momentum Through 2034, According to DelveInsight | AstraZeneca, Merck, SpringWorks Therapeutics, Healx, Pasithea Therapeutics, Fosun Pharmaceutical

The Key Neurofibromatosis Type 1 Companies in the market include – AstraZeneca and Merck, SpringWorks Therapeutics, Healx, Pasithea Therapeutics, Fosun Pharmaceutical, NFlection Therapeutics, and others.

 

DelveInsight’s “Neurofibromatosis Type 1 Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Neurofibromatosis Type 1, historical and forecasted epidemiology as well as the Neurofibromatosis Type 1 market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Neurofibromatosis Type 1 market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Type 1 Market Forecast

 

Some of the key facts of the Neurofibromatosis Type 1 Market Report:

  • The Neurofibromatosis Type 1 market size was valued ~USD 380 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In February 2025, SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company specializing in rare diseases and cancer, announced the online publication of data from the pivotal Phase 2b ReNeu trial in the Journal of Clinical Oncology (JCO). The trial evaluated mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). Previously, findings from the multi-center, single-arm ReNeu trial were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

  • In November 2024, Alexion, AstraZeneca Rare Disease, and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced positive topline results from the Phase 3 KOMET trial. This global, randomized, double-blind, placebo-controlled multicenter study is the largest of its kind in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The findings revealed that KOSELUGO, an oral and selective MEK inhibitor, achieved a statistically significant and clinically meaningful improvement in objective response rate (ORR), the primary endpoint, compared to placebo in these patients.

  • In November 2024, SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company specializing in severe rare diseases and cancer, announced the publication of data from the pivotal Phase 2b ReNeu trial. The study evaluated mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The findings are now available online in the Journal of Clinical Oncology (JCO).

  • Within the 7MM, the US recorded the highest number of Neurofibromatosis Type 1 cases in 2023, with approximately 97,300 diagnosed prevalent cases. This number is anticipated to rise throughout the forecast period.

  • Among the EU4 countries and the UK, Germany reported the highest number of Neurofibromatosis Type 1 cases in 2023, while the UK had the lowest number of cases.

  • In the US, approximately 30% of Neurofibromatosis Type 1 PN cases involved children, while adults accounted for about 70% of the cases in 2020.

  • In Japan, there were 5,500 operable and 3,900 inoperable cases of Neurofibromatosis Type 1 PN reported in 2023. These numbers are projected to rise over the forecast period.

  • Key Neurofibromatosis Type 1 Companies: AstraZeneca and Merck, SpringWorks Therapeutics, Healx, Pasithea Therapeutics, Fosun Pharmaceutical, NFlection Therapeutics, and others

  • Key Neurofibromatosis Type 1 Therapies: KOSELUGO (selumetinib), Mirdametinib, HLX-1502, PAS-004*, FCN-159, NFX-179, and others

  • The Neurofibromatosis Type 1 market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurofibromatosis Type 1 pipeline products will significantly revolutionize the Neurofibromatosis Type 1 market dynamics.

 

Neurofibromatosis Type 1 Overview

Neurofibromatosis are a group of genetic disorders that cause tumors to form on nerve tissue. There are three types of neurofibromatosis: neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2) and schwannomatosis.

 

Get a Free sample for the Neurofibromatosis Type 1 Market Report:

https://www.delveinsight.com/report-store/neurofibromatosis-type-1-nf1-market

 

Neurofibromatosis Type 1 Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Neurofibromatosis Type 1 Epidemiology Segmentation:

The Neurofibromatosis Type 1 market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Neurofibromatosis Type 1

  • Prevalent Cases of Neurofibromatosis Type 1 by severity

  • Gender-specific Prevalence of Neurofibromatosis Type 1

  • Diagnosed Cases of Episodic and Chronic Neurofibromatosis Type 1

 

Download the report to understand which factors are driving Neurofibromatosis Type 1 epidemiology trends @ Neurofibromatosis Type 1 Epidemiology Forecast

 

Neurofibromatosis Type 1 Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurofibromatosis Type 1 market or expected to get launched during the study period. The analysis covers Neurofibromatosis Type 1 market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neurofibromatosis Type 1 Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Neurofibromatosis Type 1 Therapies and Key Companies

  • KOSELUGO (selumetinib): AstraZeneca and Merck

  • Mirdametinib: SpringWorks Therapeutics

  • HLX-1502: Healx

  • PAS-004*: Pasithea Therapeutics

  • FCN-159: Fosun Pharmaceutical

  • NFX-179: NFlection Therapeutics

  • Mirdametinib: SpringWorks Therapeutics

  • NFX-179 Gel: NFlection Therapeutics, Inc.

 

Discover more about therapies set to grab major Neurofibromatosis Type 1 market share @ Neurofibromatosis Type 1 Treatment Market

 

Scope of the Neurofibromatosis Type 1 Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Neurofibromatosis Type 1 Companies: AstraZeneca and Merck, SpringWorks Therapeutics, Healx, Pasithea Therapeutics, Fosun Pharmaceutical, NFlection Therapeutics, and others

  • Key Neurofibromatosis Type 1 Therapies: KOSELUGO (selumetinib), Mirdametinib, HLX-1502, PAS-004*, FCN-159, NFX-179, and others

  • Neurofibromatosis Type 1 Therapeutic Assessment: Neurofibromatosis Type 1 current marketed and Neurofibromatosis Type 1 emerging therapies

  • Neurofibromatosis Type 1 Market Dynamics: Neurofibromatosis Type 1 market drivers and Neurofibromatosis Type 1 market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Neurofibromatosis Type 1 Unmet Needs, KOL’s views, Analyst’s views, Neurofibromatosis Type 1 Market Access and Reimbursement

 

To know more about Neurofibromatosis Type 1 companies working in the treatment market, visit @ Neurofibromatosis Type 1 Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Neurofibromatosis Type 1 Market Report Introduction

2. Executive Summary for Neurofibromatosis Type 1

3. SWOT analysis of Neurofibromatosis Type 1

4. Neurofibromatosis Type 1 Patient Share (%) Overview at a Glance

5. Neurofibromatosis Type 1 Market Overview at a Glance

6. Neurofibromatosis Type 1 Disease Background and Overview

7. Neurofibromatosis Type 1 Epidemiology and Patient Population

8. Country-Specific Patient Population of Neurofibromatosis Type 1

9. Neurofibromatosis Type 1 Current Treatment and Medical Practices

10. Neurofibromatosis Type 1 Unmet Needs

11. Neurofibromatosis Type 1 Emerging Therapies

12. Neurofibromatosis Type 1 Market Outlook

13. Country-Wise Neurofibromatosis Type 1 Market Analysis (2020–2034)

14. Neurofibromatosis Type 1 Market Access and Reimbursement of Therapies

15. Neurofibromatosis Type 1 Market Drivers

16. Neurofibromatosis Type 1 Market Barriers

17. Neurofibromatosis Type 1 Appendix

18. Neurofibromatosis Type 1 Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neurofibromatosis Type 1 Market Expected to Gain Momentum Through 2034, According to DelveInsight | AstraZeneca, Merck, SpringWorks Therapeutics, Healx, Pasithea Therapeutics, Fosun Pharmaceutical

Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma

The Key Phenylketonuria Companies in the market include – PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharmaceuticals, and others.

 

The Phenylketonuria market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Phenylketonuria pipeline products will significantly revolutionize the Phenylketonuria market dynamics.

 

DelveInsight’s “Phenylketonuria Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Phenylketonuria, historical and forecasted epidemiology as well as the Phenylketonuria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Phenylketonuria market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Phenylketonuria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Phenylketonuria Market Insights

 

Some of the key facts of the Phenylketonuria Market Report:

  • The Phenylketonuria market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In July 2025, PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that the U.S. Food and Drug Administration has approved Sephience (sepiapterin) for treating hyperphenylalaninemia in patients with phenylketonuria (PKU). The approval applies to both adults and children aged one month and older with sepiapterin-responsive PKU. Patients are required to use the drug alongside a phenylalanine-restricted diet. Valued at $3.51 billion, PTC Therapeutics has shown strong financial growth, with a 91% revenue increase over the past year and a solid 67% gross profit margin, according to InvestingPro data.

  • In July 2025, The FDA has approved sepiapterin (Sephience; PTC Therapeutics) for treating adults and children with phenylketonuria (PKU), a rare inherited metabolic disorder affecting the brain and causing phenylalanine (Phe) accumulation, as announced by PTC Therapeutics. Notably, the approval includes broad labeling, allowing its use for treating hyperphenylalaninemia (HPA) in patients aged one month and older with sepiapterin-responsive PKU.

  • In April 2025, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the Phase 3 PEGASUS trial of PALYNZIQ® (pegvaliase-pqpz) successfully met its primary efficacy goal, showing a statistically significant reduction in blood phenylalanine (Phe) levels in adolescents aged 12-17 with phenylketonuria (PKU) compared to diet alone. The safety outcomes aligned with the known profile of the drug. PALYNZIQ remains the first and only enzyme therapy approved for adults with PKU. Comprehensive results from the PEGASUS trial will be shared at an upcoming medical conference and submitted to regulatory authorities worldwide later this year to seek approval for adolescent use.

  • In December 2024, Alltrna announced the release of new preclinical data featuring its first tRNA development candidate, AP003. AP003 is a chemically engineered tRNA oligonucleotide delivered via a clinically validated, liver-targeted lipid nanoparticle (LNP) designed to read through the arginine to TGA (Arg-TGA) premature termination codon (PTC). A single dose of AP003 demonstrated strong in vivo restoration of protein production to clinically significant levels in two transgenic mouse models of Stop Codon Diseases: methylmalonic acidemia (MMA) and phenylketonuria (PKU).

  • In October 2024, PTC Therapeutics, Inc. announced that the FDA has accepted the New Drug Application (NDA) for sepiapterin, intended to treat both pediatric and adult patients with phenylketonuria (PKU). The Prescription Drug User Fee Act (PDUFA) target action date is anticipated to be communicated in the Day 74 Letter.

  • In 2023, within the EU4 and the UK, Germany held the largest market size for PKU at around USD 70 million, whereas Spain recorded the smallest market size.

  • In 2023, the United States represented the largest share of the market among the 7MM, comprising approximately 60% of the total market size.

  • Most PKU cases are identified in infants because of widespread newborn screening. Age-specific data showed that the majority of patients with PKU were 14 years or younger, accounting for nearly 60% of cases in the 7MM in 2023.

  • DelveInsight estimates that in 2023, missense mutations represented 60% of the diagnosed prevalent PKU cases, while nonsense mutations accounted for 5% in the 7MM.

  • In 2023, classical PKU had the largest number of cases in the United States, with approximately 11,000 cases reported based on severity-specific data.

  • Several major companies, including Asubio-Pharma/BioMarin Pharmaceutical, PTC Therapeutics, Synlogic, and others, are at the forefront of phenylketonuria treatment. Detailed market sizes by country and therapy type are provided below.

  • Key Phenylketonuria Companies: PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharmaceuticals, and others

  • Key Phenylketonuria Therapies: CNSA-001 (PTC923), HMI-102, SYNB1618, BMN-3017, and others

 

Phenylketonuria Overview

Phenylketonuria (PKU) is an inborn error of metabolism that is detectable during the first days of life via routine newborn screening. PKU is characterized by the absence or deficiency of an enzyme called phenylalanine hydroxylase (PAH), responsible for processing the amino acid phenylalanine. Amino acids are the chemical building blocks of proteins and are essential for proper growth and development.

 

Get a Free sample for the Phenylketonuria Market Report:

https://www.delveinsight.com/report-store/phenylketonuria-pku-market

 

Phenylketonuria Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Phenylketonuria Epidemiology Segmentation:

The Phenylketonuria market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Phenylketonuria

  • Prevalent Cases of Phenylketonuria by severity

  • Gender-specific Prevalence of Phenylketonuria

  • Diagnosed Cases of Episodic and Chronic Phenylketonuria

 

Download the report to understand which factors are driving Phenylketonuria epidemiology trends @ Phenylketonuria Epidemiological Insights

 

Phenylketonuria Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Phenylketonuria market or expected to get launched during the study period. The analysis covers Phenylketonuria market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Phenylketonuria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Phenylketonuria Therapies and Key Companies

  • KUVAN (Sapropterin Hydrochloride): Asubio-Pharma/BioMarin-Pharmaceutical

  • PALYNZIQ (pegvaliase-pqpz/rAvPAL-PEG/BMN 165): BioMarin Pharmaceutical

  • Sepiapterin (PTC923): PTC Therapeutics

  • SYNB1934: Synlogi

  • CNSA-001 (PTC923): PTC Therapeutics

  • HMI-102: Homology Medicine

  • SYNB1618: Synlogic

  • BMN-3017: BioMarin Pharmaceuticals

 

To know more about Phenylketonuria treatment, visit @ Phenylketonuria Medications

 

Phenylketonuria Market Drivers

  • The introduction of novel products

  • Increasing prevalence

  • Awareness about the disease

  • Research and development strategies

  • Widespread newborn screening program

 

Phenylketonuria Market Barriers

  • Unclear comorbidities

  • Limitations associated with the current treatment

 

Scope of the Phenylketonuria Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Phenylketonuria Companies: PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharmaceuticals, and others

  • Key Phenylketonuria Therapies: CNSA-001 (PTC923), HMI-102, SYNB1618, BMN-3017, and others

  • Phenylketonuria Therapeutic Assessment: Phenylketonuria current marketed and Phenylketonuria emerging therapies

  • Phenylketonuria Market Dynamics: Phenylketonuria market drivers and Phenylketonuria market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Phenylketonuria Unmet Needs, KOL’s views, Analyst’s views, Phenylketonuria Market Access and Reimbursement

 

Discover more about therapies set to grab major Phenylketonuria market share @ Phenylketonuria Treatment Landscape

 

Table of Contents

1. Phenylketonuria Market Report Introduction

2. Executive Summary for Phenylketonuria

3. SWOT analysis of Phenylketonuria

4. Phenylketonuria Patient Share (%) Overview at a Glance

5. Phenylketonuria Market Overview at a Glance

6. Phenylketonuria Disease Background and Overview

7. Phenylketonuria Epidemiology and Patient Population

8. Country-Specific Patient Population of Phenylketonuria

9. Phenylketonuria Current Treatment and Medical Practices

10. Phenylketonuria Unmet Needs

11. Phenylketonuria Emerging Therapies

12. Phenylketonuria Market Outlook

13. Country-Wise Phenylketonuria Market Analysis (2020–2034)

14. Phenylketonuria Market Access and Reimbursement of Therapies

15. Phenylketonuria Market Drivers

16. Phenylketonuria Market Barriers

17. Phenylketonuria Appendix

18. Phenylketonuria Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma

O’Connor Company Appoints Divya Mirchandani as Vice President of Finance

Experienced finance leader joins to support O’Connor Company’s national growth and operations.

Aberdeen, NC – Aug 13, 2025 – O’Connor Company, a leading name in commercial construction specializing in delivering high-quality projects across diverse sectors, proudly announces the appointment of Divya Mirchandani as its new Vice President of Finance.

With over a decade of leadership experience in accounting and financial operations, Mirchandani brings deep expertise in financial reporting, strategic planning, and systems optimization, specifically within the real estate and construction sectors. In her new role, she will oversee the full scope of O’Connor’s financial management, from ensuring the integrity of financial statements to providing strategic analysis that supports long-term growth.

“Divya brings the kind of steady-handed leadership and forward-thinking mindset that perfectly aligns with where we’re headed as a company,” said Clark Lowe, President and CEO of O’Connor Company.

Mirchandani started her career in audit and financial services after earning her Master of Accountancy (MAcc) degree from The College of William & Mary in 2011. Since becoming a licensed CPA in 2015, she has led complex finance operations with a focus on GAAP compliance, process improvement, and high-performance team development. She also leverages technology to streamline accounting, payroll, HR, and operational workflows, helping organizations work smarter while maintaining a people-first approach. Recognized for her clear communication and collaborative approach, Mirchandani fosters an inclusive, results-driven culture founded on trust and accountability.

“I’m excited to join a company that not only builds exceptional projects, but also prioritizes operational excellence and team development,” said Mirchandani. “I look forward to contributing to O’Connor’s growth and helping the finance team reach new heights.”

This leadership appointment marks another key step in O’Connor Company’s continued investment in talent and infrastructure as it expands its footprint across the commercial and government construction sectors.

For more information about O’Connor Company and its ongoing projects, please visithttps://www.buildoconnor.com.

About O’Connor Company

O’Connor Company is a leading name in commercial construction, specializing in delivering high-quality projects across diverse sectors. With a reputation for innovation, efficiency, and client satisfaction, O’Connor Company leverages cutting-edge practices to redefine the construction industry. From healthcare to retail and now community-focused initiatives, the company remains at the forefront of delivering projects that make a lasting impact.

Media Contact
Company Name: Otter PR
Contact Person: Mark Hashem
Email: Send Email
Phone: 7274339069
Address:100 E Pine St Suite 110
City: Orlando
State: Florida
Country: United States
Website: OtterPR.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: O’Connor Company Appoints Divya Mirchandani as Vice President of Finance

Endometriosis Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma, Enteris Bio

The Key Endometriosis Companies in the market include – AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others.

 

DelveInsight’s “Endometriosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Endometriosis, historical and forecasted epidemiology as well as the Endometriosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Endometriosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endometriosis Market Forecast

 

Some of the key facts of the Endometriosis Market Report:

  • The Endometriosis market size was valued ~USD 2,300 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In July 2025, A drug candidate once described by Organon as potentially its “biggest opportunity” has failed to meet expectations in a Phase 2 clinical trial, leading the company to discontinue its development for endometriosis. Organon, a women’s health-focused company, had acquired the drug OG-6219 through its $75 million upfront acquisition of Forendo Pharma in 2021. Following the acquisition and in an effort to expand its R&D pipeline after its spinout from Merck & Co., Organon initiated a Phase 2 trial in 2022. However, due to disappointing results, the company has now decided to halt further development of the therapy.

  • In April 2025, Aditxt, Inc. (NASDAQ: ADTX), a company focused on advancing impactful health innovations, announced that its subsidiary, Pearsanta, Inc., has secured Institutional Review Board (IRB) approval from WCG Clinical to begin a prospective clinical study. The study will assess the Mitomic® Endometriosis Test (MET), an innovative blood-based diagnostic aimed at supporting the early detection of endometriosis.

  • In March 2025, England’s NHS is set to offer the first long-term daily pill for endometriosis treatment, following a recommendation by the National Institute for Health and Care Excellence (NICE) in its final draft guidance. The medication, relugolix-estradiol-norethisterone—also known as relugolix combination therapy (relugolix CT)—is approved for adults of reproductive age who have not found relief through prior medical or surgical treatments. This marks the first time the NHS has approved a long-term therapy of this kind for endometriosis. An estimated 1,000 women each year are expected to benefit from this new treatment option.

  • In March 2025, The first long-term daily oral treatment for endometriosis has been recommended for regular use by the NHS in England. In its final draft guidance, the National Institute for Health and Care Excellence (NICE) advised that relugolix-estradiol-norethisterone be considered as a treatment option for managing endometriosis symptoms in reproductive-age adults who have not found relief from earlier medical or surgical treatments.

  • In October 2024, Lisata Therapeutics, Inc. has entered into a sponsored research agreement with the University of Cincinnati to study its innovative cyclic peptide candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor) using a preclinical animal model for endometriosis treatment.

  • In October 2024, Hope Medicine Inc. reported positive interim results from its global Phase II trial evaluating HMI-115, a monoclonal antibody targeting the prolactin receptor, for treating moderate to severe endometriosis-associated pain. The randomized, multicenter, double-blind, placebo-controlled study assesses the safety and efficacy of HMI-115 over a 12-week treatment period. As a first-in-class therapy for endometriosis, HMI-115 has also received Breakthrough Therapy Designation from China’s National Medical Products Administration (NMPA).

  • In May 2024, Neurocrine Biosciences, Inc. announced the initiation of its Phase I first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants. NBI-1117567 is an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist for the potential treatment of neurological and neuropsychiatric conditions.

  • In May 2024, TiumBio Co., Ltd., dedicated to developing innovative treatments for rare and incurable diseases, has reported positive topline results from its Phase 2a clinical trial of Merigolix. This oral gonadotropin-releasing hormone (GnRH) receptor antagonist is being evaluated for its effectiveness in managing moderate to severe endometriosis-associated pain.

  • Among the total endometriosis market size across the 7MM, the United States held the largest share, reaching approximately USD 1,400 million in 2023.

  • In 2023, the UK held the largest market share at approximately 20% within the EU4 and UK region, while Spain had the smallest share.

  • In 2023, there were approximately 10.8 million diagnosed prevalent cases of endometriosis across the 7MM, with the highest number reported in the United States.

  • Endometriosis is most prevalent among females aged 18–29, accounting for approximately 40% of all cases in the 7MM.

  • In 2023, the total number of treated endometriosis cases was approximately 2.9 million in the US, followed by the UK and France.

  • Key Endometriosis Companies: AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others

  • Key Endometriosis Therapies: ORILISSA (elagolix), MYFEMBREE (relugolix, estradiol, and norethindrone acetate), ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 µg, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, and others

  • As per the findings of Yoshino et al. (2022), around 2.6 million women in Japan are impacted by endometriosis.

  • The Endometriosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Endometriosis pipeline products will significantly revolutionize the Endometriosis market dynamics.

 

Endometriosis Overview

Endometriosis is a chronic condition in which tissue similar to the lining of the uterus (endometrium) grows outside the uterus, commonly on the ovaries, fallopian tubes, or pelvic lining. This misplaced tissue behaves like normal endometrial tissue—thickening, breaking down, and bleeding with each menstrual cycle—but has no way to exit the body, leading to inflammation, pain, and scar tissue formation. Symptoms often include pelvic pain, painful periods, infertility, and digestive issues. While there is no cure, treatment options such as hormonal therapy, pain relievers, and surgery can help manage symptoms and improve quality of life.

 

Get a Free sample for the Endometriosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/endometriosis-market

 

Endometriosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Endometriosis Epidemiology Segmentation:

The Endometriosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Endometriosis

  • Prevalent Cases of Endometriosis by severity

  • Gender-specific Prevalence of Endometriosis

  • Diagnosed Cases of Episodic and Chronic Endometriosis

 

Download the report to understand which factors are driving Endometriosis epidemiology trends @ Endometriosis Epidemiology Forecast

 

Endometriosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endometriosis market or expected to get launched during the study period. The analysis covers Endometriosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Endometriosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Endometriosis Therapies and Key Companies

  • ORILISSA (elagolix): AbbVie

  • MYFEMBREE (relugolix, estradiol, and norethindrone acetate): Myovant/Pfizer

  • ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences

  • Linzagolix (OBE2109): ObsEva/Kissei Pharmaceutical

  • Leuprolide Oral Tablet: Enteris BioPharma Inc.

  • SN132D: Spago Nanomedical AB

  • OG-6219: Iqvia Pty Ltd

  • Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical

  • Relugolix: Myovant Sciences GmbH

  • HMI-115: Hope Medicine (Nanjing) Co., Ltd

  • Quinagolide 1080 µg: Ferring Pharmaceuticals

  • OBE2109: ObsEva

  • SASHR7280: Jiangsu HengRui Medicine

  • Estradiol/Norethindrone Acetate: AbbVie

  • TAK-385: ASKA Pharmaceutical Co., Ltd.

  • NBI-56418 (GnRH antagonist): Abbott

  • KLH-2109: Kissei Pharmaceutical Co., Ltd.

  • Dienogest (Visanne, BAY86-5258): Bayer

  • ERB-041: Pfizer

 

Discover more about therapies set to grab major Endometriosis market share @ Endometriosis Treatment Landscape

 

Endometriosis Market Strengths

  • The rising prevalence of endometriosis is the primary strength of its global market, leading to more focus by pharmaceutical firms

  • At national and international levels, government and key market players actively invest in research and development and increase funds, further catering to market growth.

 

Endometriosis Market Opportunities

  • Incumbents are paired with healthcare providers to raise awareness in the field of endometriosis at the physician and patient levels

  • New diagnostic tools and techniques or methods can be explored for the early detection of endometriosis in the affected patient pool

 

Scope of the Endometriosis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Endometriosis Companies: AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others

  • Key Endometriosis Therapies: ORILISSA (elagolix), MYFEMBREE (relugolix, estradiol, and norethindrone acetate), ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109) , Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 µg, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, and others

  • Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies

  • Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Endometriosis Unmet Needs, KOL’s views, Analyst’s views, Endometriosis Market Access and Reimbursement

 

To know more about Endometriosis companies working in the treatment market, visit @ Endometriosis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Endometriosis Market Report Introduction

2. Executive Summary for Endometriosis

3. SWOT analysis of Endometriosis

4. Endometriosis Patient Share (%) Overview at a Glance

5. Endometriosis Market Overview at a Glance

6. Endometriosis Disease Background and Overview

7. Endometriosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Endometriosis

9. Endometriosis Current Treatment and Medical Practices

10. Endometriosis Unmet Needs

11. Endometriosis Emerging Therapies

12. Endometriosis Market Outlook

13. Country-Wise Endometriosis Market Analysis (2020–2034)

14. Endometriosis Market Access and Reimbursement of Therapies

15. Endometriosis Market Drivers

16. Endometriosis Market Barriers

17. Endometriosis Appendix

18. Endometriosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Endometriosis Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma, Enteris Bio

MC Business Advisors Expands Brokerage Services to Support Business Transitions in Today’s Evolving Market

MC Business Advisors Expands Brokerage Services to Support Business Transitions in Today’s Evolving Market
MC Business Advisors, a trusted name in lower-middle-market business transactions, has announced the expansion of its advisory services aimed at supporting business owners, buyers, and investors during a critical time of economic change. With the growing number of ownership transitions nationwide, the firm is reinforcing its position as a reliable partner in facilitating successful sales, acquisitions, and valuations for privately held companies.

With the current wave of baby boomer retirements, more companies are entering the market than ever before. MC Business Advisors recognizes the demand for specialized support in navigating these transitions. By combining market expertise with strategic advisory insight, the firm provides a full suite of services to help clients plan for, prepare, and execute smooth transactions across multiple industries. These services include market readiness assessments, financial benchmarking, exit strategy planning, and targeted buyer identification.

For owners seeking to list a business for sale, MC Business Advisors offers professional valuation, deal structuring, and confidential marketing strategies designed to reach serious and qualified buyers. The firm’s team ensures sellers are equipped with the data, insights, and support necessary to present their businesses competitively and with integrity. Each listing is managed discreetly, preserving business continuity while increasing market visibility among vetted investors.

Business owners who are thinking, “How do I sell my business in today’s market?” are turning to MC Business Advisors for answers. The firm’s approach includes preparing financials, identifying growth opportunities, and creating a transition plan tailored to each client’s goals. Sellers benefit from the firm’s national network and curated buyer database, which includes private equity groups, strategic buyers, and individual investors. The firm also provides seller coaching to increase readiness and maximize value throughout the process.

The firm also supports investors and entrepreneurs looking to buy a business. With a growing inventory of quality listings, MC Business Advisors helps buyers identify opportunities that match their financial and operational criteria. In-depth due diligence support, lender introductions, and deal negotiation services are also provided to ensure informed decisions and sustainable outcomes. Many buyers find added value in the firm’s ability to clarify business performance, operational risks, and future potential.

As an experienced business broker, MC Business Advisors bridges the gap between sellers and buyers with professionalism, confidentiality, and results-driven planning. The team handles complex deals with discretion and transparency, ensuring that all parties are supported throughout the process. The firm also provides post-sale transition consulting to help ensure long-term success for both buyer and seller. This includes support with management training, staff retention strategies, and operational handoff planning.

With increasing demand for local expertise, MC Business Advisors is also responding to more searches for business brokers near me by expanding its regional coverage throughout the Midwest and beyond. The firm is actively building partnerships with attorneys, accountants, and financial institutions to serve clients at a local level while maintaining national reach. Plans are underway to open additional advisory offices in key metro markets.

MC Business Advisors remains committed to helping clients build, transition, and preserve business value. With a reputation for excellence and a strategic, tailored approach, the firm continues to be a trusted resource for business owners, buyers, and investors seeking clarity and confidence during pivotal moments.

Media Contact
Company Name: MC Business Advisors
Contact Person: Michael Crow
Email: Send Email
Phone: (678) 680-5001
Address:4840 Old National Hwy
City: College Park
State: GA
Country: United States
Website: https://mcbizadvisors.com/

Lyons Contracting Strengthens Roofing Solutions for Alexandria Community

Lyons Contracting announces the expansion of its comprehensive roofing offerings throughout Alexandria, enhancing protection for both residential and commercial properties. With a focus on craftsmanship and clear communication, the company is committed to helping local structures withstand seasonal changes and maintain long‑term durability.

Seamless New Roof Installations

When a home or business requires a comprehensive roofing project, Lyons Contracting brings seasoned expertise and meticulous attention to detail. Through the Roof Installation Alexandria service, skilled crews conduct thorough assessments to evaluate the roof deck condition, ventilation needs, and material compatibility. Each installation follows a carefully planned sequence, from secure underlayment placement to precision‑cut shingles, resulting in watertight surfaces that integrate with a building’s architectural style.

Swift Repairs for Unexpected Leaks

Nothing disrupts daily life faster than a sudden drip from above. Lyons Contracting’s technicians respond quickly to diagnose and address breaches, utilizing infrared moisture detection and targeted patching techniques. The Roof Leak Repair Alexandria program includes identifying underlying issues—such as worn flashing, cracked tiles, or failed sealants—followed by repairs designed to prevent recurrence. Emergency tarping and temporary measures are also available when weather conditions demand immediate protection.

Ongoing Roofing Maintenance and Inspections

Beyond installations and repairs, regular upkeep can extend a roof’s service life and uncover minor concerns before they escalate. The company’s Roofing Services Alexandria encompass scheduled inspections, gutter cleaning, and sealant renewal. By fostering open dialogue with property managers and homeowners, Lyons Contracting ensures maintenance plans align with occupancy schedules and budget considerations, all while reinforcing the structure’s resilience against mold, moss, and structural fatigue.

Lyons Contracting balances technical proficiency with a community‑minded approach—explaining each step of a job in clear terms, respecting on‑site routines, and offering practical advice for seasonal preparation. Whether welcoming new neighbors or tending to long‑standing clients, the team treats every roof as a canvas for safety and neighborhood pride.

About Lyons Contracting

Lyons Contracting is a family‑owned construction firm based in Alexandria, Virginia. Specializing in roofing installations, leak repairs, and preventative maintenance, the company emphasizes quality workmanship, transparent communication, and local engagement. Through ongoing training and equipment investments, Lyons Contracting remains committed to maintaining the structural integrity and curb appeal of properties throughout the community.

Media Contact
Company Name: Lyons Contracting
Contact Person: Tom Petrilli
Email: Send Email
Phone: (703) 299-8888
Address:4930 A Eisenhower Ave
City: Alexandria
State: Virginia
Country: United States
Website: https://lyonscontracting.com/

Sparks Law Firm Expands Criminal Defense Services in Colleyville Amid Rising Legal Demand

Sparks Law Firm Expands Criminal Defense Services in Colleyville Amid Rising Legal Demand
Sparks Law Firm has announced the strategic expansion of its criminal defense services throughout Colleyville in response to increasing legal challenges faced by residents. The move follows a noticeable rise in criminal charges in the region, particularly related to DWI and misdemeanor offenses.

The firm has experienced a consistent uptick in case volume over the past year, prompting a deeper investment in resources, personnel, and case management tools. By strengthening its local presence, Sparks Law Firm aims to improve access to timely legal counsel and build upon its longstanding reputation in the Tarrant County court system.

The legal team at Sparks Law Firm has emphasized the importance of adaptability in today’s legal climate, citing evolving law enforcement strategies and changes in prosecutorial priorities. The firm’s attorneys are now taking on a broader range of cases, including felony-level charges, domestic violence, and probation violations.

Colleyville Criminal Defense Lawyers within the firm have also participated in continuing education programs, ensuring they are prepared for increasingly complex legal scenarios. Several attorneys have assumed leadership roles in regional legal associations, further solidifying the firm’s reputation as a trusted source of insight in North Texas.

Additionally, Sparks Law Firm has established a specialized response team to handle cases involving alcohol-related offenses. The Colleyville DWI Lawyer team will manage all aspects of DWI cases, from license hearings to trial. This expansion ensures thorough, efficient representation across a category of charges that continues to grow annually.

With the demand for experienced Colleyville Criminal Defense Lawyer representation on the rise, the firm’s latest developments position it as a committed ally in the criminal justice system. The expansion marks a proactive step toward meeting the region’s increasing legal needs with confidence, skill, and consistency.

Media Contact
Company Name: Sparks Law Firm
Contact Person: Justin Sparks
Email: Send Email
Phone: (817) 334-0300
Address:603 E Belknap St
City: Fort Worth
State: Texas
Country: United States
Website: https://www.sparkslawfirm.com/fort-worth-dwi-lawyer